Skeletal muscle atrophy is an important feature of cancer cachexia, which can be induced by
chemotherapy, and affects the survival and quality of life of cancer patients seriously. No …

Cisplatin (DDP) is a commonly used chemotherapy drug, but DDP can cause skeletal
muscle atrophy and cachexia. This study combined the DDP-induced C2C12 myotube …

Cisplatin (DDP), a widely used chemotherapeutic drug in cancer treatment, causes oxidative
stress, resulting in cancer cachexia and skeletal muscle atrophy. This study investigated the …

Background Cachexia has a devastating impact on survival and quality of life for many
cancer patients and contributes to nearly one‐third of all cancer deaths; also, it is associated …

Background Cancer cachexia is a lethal metabolic syndrome induced by cancer and
chemotherapy administration and characterized by marked muscle wasting. Although …

Skeletal muscle atrophy, the most prominent phenotypic feature of cancer cachexia, is often
observed in cancer patients undergoing chemotherapy. Magnolol (M) extracted from …

Cisplatin (DDP) is widely used in cancer treatment, but DDP can cause skeletal muscle
atrophy and cachexia. This study explored the effect and mechanism of daidzein (DAI) in …

Background Cancer cachexia is a serious metabolic disorder syndrome that is responsible
for the deaths of approximately 30% of patients with cancer, but effective drugs for cancer …

Cancer cachexia is a complex disorder characterized by inflammatory responses, and it is
associated with poor performance status and high mortality rate of cancer patients …

Abstract Background Corylifol A (CYA) is one of the main active components of Psoralea
corylifolia L. CYA had been reported to have ameliorating effects on dexamethasone …